C 1101
Alternative Names: C-1101Latest Information Update: 09 Dec 2025
At a glance
- Originator Consano Bio
- Class Analgesics; Proteins
- Mechanism of Action Protein replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Radiculopathy
Most Recent Events
- 09 Dec 2025 Consano Bio anticipates to submit IND application in Radiculopathy in in the second quarter of 2025 (Consano Bio pipeline, December 2025)
- 09 Dec 2025 Consano Bio plans clinical trials in Radiculopathy in USA (Consano Bio pipeline, December 2025)
- 04 Dec 2025 Phase-I clinical trials in Radiculopathy in Australia (Epidural) (NCT07264270)